Tempest Therapeutics Inc (TPST)
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
$0.53-1.24%
Close 2026-10-29 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
Research Workspace
Put TPST beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Reduce losses and improve EPS: Comparison needs review.
View ThesisRevenue is contracting — down about 9% over the past year.
View GrowthManagement screens weak on earnings delivery, margins.
View ManagementThis stock is highly volatile — it swings about 3% on a typical day and fell roughly 95% in its worst 12-month stretch.
View RiskTPST depends on integrating acquired CAR-T assets and starting a registrational study. That effort matters amid unprofitability and weak recent financial performance. The latest reported quarter missed GAAP EPS consensus by 13.3%. Revenue growth cannot be judged because the desk provides no revenue figure. The desk omits valuation multiples and a priced-in expectations read. So, the price’s reflection of the CAR-T opportunity cannot be established. Our model puts the next-quarter miss probability near 78%. The thesis pillar to reduce losses and improve EPS needs review. This read is provisional.
Trailing returns as of 2026-10-29. TPST is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 1 analyst currently covering TPST (as of Oct 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare TPST with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| TPST Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put TPST next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Complete integration of acquired CAR-T assets and initiate registrational study
Senlang CAR-T deal enhances CAR-T asset integration.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-29. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Advances: Complete integration of acquired CAR-T assets and initiate registrational study
Option deal supports CAR-T platform development.
Advances: Strengthen business development and strategic partnerships
Funding supports business development and strategic partnerships.
Threatens: Manage executive transitions
Resignations could hinder management's talent stability efforts.